Pomanox石榴提取物12周随机三盲试验:面部色斑黑色素指数主要终点未达统计学显著
Effects of pomegranate extract Pomanox on facial skin aging parameters: a randomized triple-blind placebo-controlled trial
一项在西班牙开展的随机三盲安慰剂对照试验纳入66名女性,每日服用石榴提取物Pomanox(367 mg或700 mg)12周,面部色斑黑色素指数的主要纵向分析未达统计学显著(组×访视交互P=0.158)。次要分析显示367 mg组12周黑色素指数降幅比安慰剂高11.3%(95% CI −21.9%至−0.69%)。皮肤水合、弹性以及皮肤与肠道菌群的变化被作者列为探索性结果,需更大样本研究确认。
Introduction
Skin aging is a multifaceted process driven by intrinsic and extrinsic mechanisms, particularly UV radiation1,2. Exposure to UV radiation involves a variety of interrelated molecular and cellular systems, including oxidative stress, increase of reactive oxygen species (ROS), lipid peroxidation of cell membranes, activation of inflammatory cascades, and structural damage of extracellular matrix (ECM) proteins3,4,5,6,7,8 as well as alterations in the skin and gut microbiota9,10. Skin anti-aging therapies, aimed at mitigating the effects of aging and its impact on well-being, target some of these underlying mechanisms11. Recently, the benefits of oral antioxidant supplements have been a focus of increasing interest12. It has been shown that the consumption of polyphenolic compounds derived from natural extracts can improve skin elasticity, photosensitivity, hydration, wrinkle depth, and pigmentation spots13,14.
Fruits rich in polyphenols, such as pomegranate (Punica granatum L.), are important sources of bioactive compounds with antioxidant and anti-inflammatory properties. Pomanox P30, a standardized pomegranate fruit extract (PE) with a high content of the ellagitannin punicalagin15 has shown health benefits in in vitro and human studies mainly due to its anti-inflammatory and antioxidant effects in a variety of conditions. Therapeutic effects associated with PE include decrease of inflammatory markers, reduction of blood pressure and cortisol levels with improvement of endothelial function16,17, modulation of different parameters associated with satiety18 and physical performance19, mitigation of oxidative stress in age-related decline promoting healthy aging20,21, and potential cognitive benefits in older adults22,23. The biological effects of pomegranate are primarily attributed to its urolithin metabolites, such as urolithin A, which are produced through the catabolism of its polyphenolic compounds including ellagitannins and ellagic acid (EA) by the gut microbiota20. Other studies have demonstrated skin health benefits from various pomegranate products rich in polyphenols2,24,25,26.
In a previous study in human foreskin fibroblasts Hs68 line, the same PE had positive effects on collagen and hyaluronic acid metabolism and inhibited ROS production and tyrosinase activity15. Based on these results, it was hypothesized that consumption of PE could exert beneficial effects on skin aging in humans, particularly by reducing hyperpigmentation and modulating other biomarkers of photoaging. Thus, the main objective of this study was to evaluate the impact of supplementation with PE on hyperpigmented facial skin spots and other facial skin aging-related parameters.
Methods
Design and participants
This was a single-center, randomized, parallel-arm, triple-blind and placebo-controlled trial conducted at the Eurecat Nutrition and Health Unit in Reus, Tarragona (Spain) between June 2023 and March 2024. Participants were recruited through newspaper, bulletin board, and social media advertisements. Inclusion criteria were women aged ≥ 30 years and ≤ 65 years, Fitzpatrick skin phototype II-IV, presence of hyperpigmentation in a facial spot, and signed informed consent. Exclusion criteria were body mass index (BMI) ≥ 35 kg/m²; presence of any cutaneous disease or skin alteration in the facial study area; diagnosis of inflammatory or functional bowel disease within the past 6 months; chronic diarrhea; anemia; history of bariatric surgery; any chronic disease with symptoms and/or pharmacological treatment that may interfere with participation in the study; current smoking; chronic alcohol consumption; use of antioxidant, multivitamin, or phytotherapeutic supplements; treatment with oral contraceptives, hormones, or antibiotics within the past 30 days; topical treatments for acne, photoaging, or to improve skin appearance within the past 6 months; pregnancy or intention to become pregnant; breastfeeding; current or past participation in a clinical trial or consumption of a research product within 30 days prior to inclusion; hypersensitivity or intolerance to any component of the study product; and inability to understand the study procedures.
The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Institut d’Investigació Sanitària Pere Virgili (IISPV) (code 079/2023, approval date March 30, 2023) (Reus, Tarragona, Spain) and was registered in the ClinicalTrials.gov (NCT05842447; date of registration May 6, 2023). All participants gave written informed consent.
Intervention and study procedures
Participants were randomly assigned to supplementation with one of two doses of the PE (367 and 700 mg) or supplementation with placebo using block randomization with 1:1:1 allocation and block sizes of 6. The randomization schedule was generated through Randomization.com (https://www.randomization.com) accessed on June 20, 2023 by an independent investigator. The study was triple-blind, with participants, researchers, and the biostatistician blinded to randomization.
The intervention included the administration of two daily doses of PE, in capsules containing either 367 mg (125 mg of punicalagins α and β) or 700 mg (238 mg of punicalagins α and β) of extract, or a placebo consisting of maltodextrin (GLUCIDEX 19D), which is not a resistant starch, it is rapidly absorbed in the intestine and exhibits low fermentability. Both PE formulations and matching placebo capsules were supplied by Euromed S.A. (Mollet del Vallés, Barcelona, Spain) and were identical in appearance and packaging. The PE was prepared according to patent EP1967079B1, using an eco-friendly and proprietary water-based extraction process (Pure-Hydro Process) and standardized to punicalagins α and β ≥ 30%. Participants were instructed to take one capsule of the assigned supplement daily, 30 min before dinner (with water if necessary) for 12 consecutive weeks. They were asked to maintain their dietary habits and lifestyle activities, and to continue their regular facial cleansing and moisturizing routines but to avoid anti-aging cosmetics and exposure to sunlight or artificial UV radiation. Consumption of ellagitannins-rich foods, including pomegranate, berries, chestnuts, and nuts was forbidden.
The study included a pre-selection visit (V0) to assess the eligibility criteria and to select the test sites (i.e., facial spot and facial spotless areas), a baseline visit (visit 1, V1), a control at 4 weeks (visit 2, V2), and a final visit at the end of the study at 12 weeks (visit 3, V3). The informed consent was signed at V0. At V1, a complete medical history was taken, anthropometric variables were measured, and a blister pack with 35 capsules of the supplement for 1-month supply was provided. Other data recorded included evaluation of facial skin areas, administration of the Physical Activity Questionnaire (IPAQ) to control physical exercise, and assessment of dietary habits using a food frequency questionnaire27. Facial skin samples, fasting blood samples as well as morning urine and fecal samples were also collected. At V2, the same procedures as at V1 were performed, except for the collection of blood, urine, and fecal samples. Blister packs containing 65 capsules of the supplement for 2-months supply were provided, and the leftover capsules returned from those given at V1 were counted. At V3, the same procedures as at V1 were performed. Leftover capsules from blister packs given at V2 were counted. Treatment compliance was defined as consumption of at least 80% of the assigned product. Any adverse events (AEs) reported by participants were recorded at visits V2 and V3.
Study variables and data collection
Body weight and body composition (body fat and muscle mass) were measured using a body composition analyzer (Tanita SC 330-S, Tanita Corp., Barcelona, Spain). Height was measured with a wall-mounted stadiometer (Tanita Leicester HR-001).
Facial skin measurements were taken under controlled room humidity and temperature, with participants acclimatizing beforehand. Participants arrived with clean cosmetic-free skin for at least 2 h prior to the study visit. Facial skin parameters included the melanin index (MI) of a facial spot, the erythema index (EI) of a facial spot, and MI of spotless skin, measured using the Mexameter MX18 (Courage+Khazaka electronic GmbH, Köln, Germany). Additionally, the selected facial spot was analyzed with the DermoPrime system for assessment of skin pigmentation. Skin wrinkles, hydration, pores, acne, keratin, and elasticity were assessed using the DermoPrime system. Wrinkles were measured around the participant’s right eye; hydration was assessed in three areas on the right side of the face (forehead, cheekbone, and jawline); pores and acne were evaluated on the right cheek; and keratin was measured on the right cheekbone. Skin elasticity was measured using the Cutometer MPA 580 device (Courage+Khazaka electronic GmbH) on the upper neck area adjacent to the right chin. For MI, EI, wrinkles, hydration, pores, acne, and elasticity, measurements were taken in triplicate and the average value was considered.
Laboratory tests included skin-related serum biomarkers related to the following pathways: (a) collagen and hyaluronic acid metabolism (procollagen type 1 N-terminal propeptide [PINP], procollagen type I carboxy-terminal propeptide [PICP], hyaluronic acid, hyaluronidase, and MMP-1); (b) inflammation (interleukin [IL]-1α and IL-6); and (c) glycation metabolism (pentosidine and carboxymethyl lysine [CML]. In addition, the following biomarkers were determined in urine: dimethyl-ellagic acid glucuronide (DMEAG), urolithin A glucuronide (UAG), 8-hydroxy-2’-deoxyguanosine (8-OHdG), thiobarbituric acid reactive substances (TBARS), and ferric reducing antioxidant power (FRAP). Analyses were performed using commercial enzyme immunoassay and colorimetric kits following the manufacturer’s protocols. Urinary levels of DMEAG were analyzed using ultra-high-performance liquid chromatography-electrospray ionization tandem mass spectrometry (UHPLC-ESI-MS/MS).
Facial skin samples were collected from the right forehead, cheek, and chin by rubbing each area 20 times with a sterile swab. Stool samples were stored at -20 °C, transported refrigerated to the study center, and stored at -80 °C until analysis. Skin and fecal microbiota were analyzed by PCR amplification of the V4 region of the 16 S rRNA gene following the Ion Torrent sequencing library preparation protocol. PCR products were analyzed by agarose gel electrophoresis and quantified using microfluidic electrophoresis (Agilent Technologies, Santa Clara, CA, USA). Individual libraries were pooled in equimolar amounts and sequenced on the GeneStudio S5 System (Life Technologies, Carlsbad, CA, USA). Sequences were then analyzed using the QUIIME platform (2-2020.8), filtering the sequences with DADA2, and grouping them into amplicon sequence variants (ASVs). Taxonomy was assigned to the ASVs using a Naïve-Bayes classifier trained on the SILVA reference database and alpha (α) and beta (β) diversity metrics were determined.
Study outcomes
The primary outcome was the change of MI of a facial spot at 12 weeks as compared with baseline. Secondary outcomes were changes of other skin-related parameters, serum biomarkers, urinary levels of DMEAG and UAG, and facial skin and gut microbiota.
Statistical analysis
Sample size
The sample size was calculated using the G*Power version 3.1 software considering a decrease of at least 12% in MI in the PE arms compared with placebo, which is similar to changes found in other pomegranate supplementation studies2,24. Based on a baseline mean (± standard deviation, SD) of MI values of 177.9 ± 21.9 previously reported28,29,30, for a statistical power of 80%, a confidence interval (CI) of 95% and using a Student’s t test for independent samples, 18 participants per group were required, which was increased to 22 participants assuming a 20% dropout rate.
Facial skin parameters and skin-related biomarkers
Data normality was tested with the Shapiro-Wilk and Kolmogorov-Smirnov tests. Categorical variables are expressed as frequencies and percentages, and continuous variables as mean and SD or median and interquartile range (IQR), with the 95% confidence intervals (CIs). Baseline differences in the study variables between treatment groups were assessed using analysis of variance (ANOVA), Welch’s one-way ANOVA, or the Kruskal-Wallis test, followed by Bonferroni post hoc comparisons for pairwise analysis. Between-group differences in facial skin variables after 4 and 12 weeks of treatment were analyzed using linear mixed-effects models (LMM) with a group-by-visit interaction, participant-level random intercepts, and adjustment for age. Residuals from all models were assessed for normality and homoscedasticity. Post hoc tests were performed for variables showing a significant group-by-visit interaction. Between-group differences were also evaluated using analysis of covariance (ANCOVA), with the percentage change for facial skin variables and absolute change for other variables at each visit relative to baseline as the dependent variable, adjusted for baseline values. Additionally, comparisons between treatments were performed using Student’s t test or the Mann-Whitney U test. Within-group differences between baseline values and data at each study visit were assessed using paired Student’s t test or Wilcoxon signed-rank test. The relationships of between DMEAG and UAG urinary levels and the percentage of change in MI in PE-treated groups as well as changes in oxidative stress-related biomarkers in all groups were analyzed with the Spearman’s rank-order correlation coefficient. Analyses were performed on the modified intention-to-treat (mITT) population (i.e., randomized participants who received at least one dose of the assigned study product). Facial skin outcomes were also analyzed in the per-protocol (PP) dataset (i.e., participants who completed the study). Statistical significance was set at P < 0.05. No imputation for missing data was performed and LMMs assumed missing data at random. Outliers (1 participant from the 700 mg group excluded from MI analysis, and 1 participant from the 367 mg group excluded from pore analysis) were identified using boxplot visualization and the interquartile range (IQR) method. Sensitivity analyses including and excluding these outliers, and the overall direction of the results remained consistent, although the refined dataset provided a more accurate estimation of the treatment effect.
In summary, the LMM specifically evaluating group-by-visit interaction was the prespecified primary analysis for the primary outcome (MI of a facial spot); LMMs were also applied to secondary outcomes (skin pigmentation, MI of spotless skin, hydration, and elasticity); pairwise comparisons between groups using Bonferroni correction were performed when a significant main effect or interaction was identified in the LMM models; and analyses of percentage changes from baseline and comparisons using ANCOVA or t-tests/Mann-Whitney U tests at specific time points were considered exploratory. The IBM SPSS 26 statistics software (IBM Corp., Armonk, NY, USA) and R version 4.4.2 (R Core Team) were used for data analyses. Linear mixed-effects models were fitted using the lme4 package version 1.1–35.5 in R.
Microbiota analysis
Within-group changes in abundant taxa across visits were analyzed with the Wilcoxon signed-rank test. For between-group comparisons, delta values were calculated, and taxonomic categories with < 1% representation were excluded. The Kruskal-Wallis test was used for assessment of the remaining taxa at family and genus levels. The Wilcoxon and Kruskal-Wallis analyses were corrected for multiple comparisons using the false discovery rate (FDR), but no statistically significant differences were observed after this correction. Therefore, results reported were not adjusted for multiple comparisons. Alpha diversity (Shannon and Chao1 indices) and β diversity (Principal Coordinates Analysis based on Bray-Curtis dissimilarity and Weighted UniFrac distance) metrics were used to evaluate treatment-induced overall changes in microbial community structure. Differences in α diversity were analyzed using the Kruskal-Wallis test, and differences in β diversity using permutational multivariate analysis of variance (PERMANOVA) and analysis of similarities (ANOSIM). Microbiota analyses, however, were exploratory.
Results
Study population
Of 82 women assessed for eligibility, 66 were randomized, with 22 allocated to each study group. One participant in the PE 367 mg and another in the placebo group did not receive the allocated product, so that the mITT dataset included 21 participants administered with PE 367 mg, 22 with PE 700 mg, and 21 with placebo (Fig. 1). Baseline data were similar in all study groups, although muscle mass was significantly greater in the PE 367 mg vs. the placebo group (Table 1).
Flow chart of the study population (mITT: modified intention-to-treat population; PP: per-protocol population).
Changes of MI, pigmentation, and other skin-related parameters
In relation to the primary endpoint (Table 2), MI values of a facial spot showed statistically significant decreases at 4 and 12 weeks in both PE groups, as well as in the placebo group at 12 weeks as compared with baseline (Fig. 2A). The primary mITT LMM analysis showed a global group-by-visit interaction of P = 0.158 (F (2, 116) = 1.87) for the facial spot MI. For the PE 367 mg group compared to placebo, the estimated treatment effect per visit was − 7.27 units (95% CI − 16.12 to 1.58; P = 0.106). For the PE 700 mg group, the estimated rate of change per visit was 0.39 units (95% CI − 8.12 to 8.90; P = 0.928). Additionally, a sensitivity analysis was performed by excluding a participant previously identified with a technical measurement error. The results of this sensitivity analysis were consistent with the primary mITT findings (P = 0.185; F (2, 114 ) = 1.708), confirming the robustness of the data regardless of the inclusion or exclusion of this outlier. These results indicate that although a numerically larger reduction in spot MI was observed in the 367 mg group compared to placebo, this difference did not reach statistical significance within the primary longitudinal model.
Mean and percentage of changes of melanin index (MI) of a facial spot (panels A and B), pigmentation of a facial spot (panels C and D), and MI of spotless facial skin (panels E and F). *P < 0.05 for within-group comparisons vs. baseline using the Student’s t test for paired samples (panels A, C, and E); *P < 0.05 for between-group comparisons vs. placebo (total change minus baseline) using the Student’s t test or the Mann-Whitney U test for independent samples (Pom: Pomanox pomegranate extract; w: weeks).
As a secondary analysis, the percentage of change of MI after 4 weeks of treatment was similar in the three study groups, but the 367 mg dose group had a significantly higher decrease in the percentage of change of MI at 12 weeks as compared with placebo (mean difference of − 11.3%, 95% CI − 21.9 to − 0.69%) (Supplementary Table S1) (Fig. 2B).
Pigmentation of a facial spot decreased significantly at 4 and 12 weeks in the three study groups (Fig. 2C), and there was a significant interaction between the intervention and the study visit (Table 2). Post hoc analyses showed significant differences between the PE 367 mg group as compared with placebo (unadjusted P = 0.032) and PE 700 mg (unadjusted P = 0.020). The percentage of decrease in spot pigmentation at 4 weeks was statistically significant for the comparison of PE 367 mg and placebo (Fig. 2D) (mean difference of -11.8%, 95% CI − 22.8 to − 0.81) (Supplementary Table S1).
Changes of MI values of spotless skin showed significant decreases in both PE groups at 4 and 12 weeks and in the placebo group at 12 weeks as compared with baseline (Table 2) (Fig. 2E). The interaction between the intervention and the study visit was statistically significant. Post hoc analysis showed a significant difference between the 367 mg dose and placebo (adjusted P = 0.006). Moreover, the percentage of change of MI of spotless skin was higher in the PE 367 mg group as compared with placebo, both at 4 and 12 weeks (Fig. 2F) (Supplementary Table S1).
Skin hydration decreased significantly at 12 weeks in the placebo group only (Table 2) (Fig. 3A). As exploratory analysis, the percentage of change in the PE 367 mg group was significantly higher vs. placebo at 12 weeks (mean difference 23.9, 95% CI 4.42 − 43.4) (Fig. 3B) (Supplementary Table S2). Elasticity increased in both active groups at 12 weeks as well as in the PE 700 mg group at 4 weeks as compared with baseline (Table 2) (Fig. 3C). In relation to skin elasticity and as exploratory analysis, the PE 700 mg group showed a trend toward statistical significance at 4 and 12 weeks vs. placebo (Fig. 3D) (Supplementary Table S2). Keratin values decreased significantly in all study groups at 12 weeks as compared with baseline (Table 2; Fig. 3E), although the mean percentages of decrease were similar in all study groups (Fig. 3F). Results for all facial skin-related variables, with and without significant changes at 4 or 12 weeks in the three study groups, are shown in Supplementary Table S2.
Mean and percentage of changes of facial hydration (panels A and B), elasticity (panels C and D), and keratin (panels E and F). *P < 0.05 for within-group comparisons vs. baseline using the Student’s t test for paired samples (panels A, C, and E); *P < 0.05 for between-group comparisons vs. placebo (total change minus baseline) using the Student’s t test or the Mann-Whitney U test for independent samples (Pom: Pomanox pomegranate extract; w: weeks).
There were two participants who were non-UAG producers, but results of skin-related parameters after excluding these cases were similar except for elasticity. In fact, the percentage of change of elasticity for PE 700 mg was significant at 12 weeks (P = 0.048), with a difference as compared with placebo of 12.2% (95% CI 0.09 to 24.3).
The same results for all skin-related parameters were obtained in the PP dataset.
Serum and urine biomarkers
Serum and urine biomarkers did not show within-group and between-group significant differences, except for decreases of GSH levels in the placebo and PE 700 mg groups at 12 weeks compared to baseline levels. Interestingly, inter-treatment analysis showed a tendency to increase GSH levels with PE 367 mg after 12 weeks of treatment compared to placebo. In addition, a tendency for increasing SOD levels as compared with baseline, and a non-statistically significant decrease of TBARS vs. placebo at 12 weeks for the PE 367 mg group was observed (Supplementary Table S3). No significant within-group or between-group differences were observed for collagen metabolism biomarkers (PINP, PICP, and MMP-1) (Supplementary Table S3).
Results of urinary DMEAG and UAG concentrations are shown in Table 3. After the intervention, DMEAG and UAG levels increased significantly in both PE groups, whereas changes in the placebo group were not significant, supporting high compliance with the intervention by study participants. Levels of DMEAG and UAG were higher in the 700 mg dose group than in the placebo and 367 mg group, particularly DMEAG values which were almost twofold greater than 367 mg group. DMEAG levels correlated significantly with TBARS in the PE 367 mg group (rho = 0.533, P = 0.023).
Skin and gut microbiota
No statistically significant differences were observed after false discovery rate correction for skin and microbiota analyses. Therefore, the reported results were not adjusted for multiple comparisons and should be considered exploratory, with P values corresponding to unadjusted post hoc P values.
Changes of skin microbiota at 12 weeks as compared with baseline showed significant decreases of Firmicutes_A in all study groups at the phylum level, increases of Enterococcacea in all groups, and increases of Lactobacillaceae and Bifidobacteriaceae in the PE groups at family level (unadjusted post hoc P values). At the genus level (Fig. 4A), Lactobacillus and Bifidobacterium increased with PE treatment, and an unclassified Enterococcaceae genus rose in all groups (unadjusted post hoc P values). The PE 367 mg group showed significant decreases in Gemella and Neisseria, whereas Proteus decreased in the placebo group (unadjusted post hoc P values) (Fig. 4A).
Relative abundance of the facial skin (A) and gut (B) microbiota at the genus level at baseline (V1) and after the 12-week intervention (V3) in the placebo, POM-367 and POM-700 groups. Stacked bar plots show the mean relative abundance of the most prevalent genera (> 1% in at least one group). Tables summarize the main significant genus-level changes (PE: Pomanox pomegranate extract; V: visit).
Between-group comparisons showed significant (unadjusted post hoc P < 0.05) differences in Bacteroidaceae, Coriobacteriaceae, UBA932, and Burkholderiaceae_A_580492 bacterial families for PE 367 mg vs. placebo, and Fusobacteriaceae, Micrococcaceae, and CAG-313 for PE 700 mg vs. placebo. At the genus level, both doses of extract significantly affected Paramuribaculum and Dorea A vs. placebo, but PE 367 mg affected Alistipes_A_871404, Fusicatenibacter, Fimenecus, Lacticaseibacillus, Lactococcus_A_343473, Limivicinus, RUG13077, CAG-83, ER4, and Akkermansia, whereas 700 mg affected Eisenbergiella, Ruminococcus_E, CAG-313, and Ruminiclostridium_E (unadjusted post hoc P values). Complete results for all significant taxa are provided in Supplementary Table S4.
In the gut microbiota, there was a significant increase of Bacteroidota in both PE groups at the phylum level (unadjusted post hoc P values). At the family level, PE 367 mg increased Dialisteraceae, whereas the 700 mg dose increased Bacteroidaceae and decreased Oscillospiraceae, Acutalibacteraceae, and CAG-74 (unadjusted post hoc P values). At the genus level, Prevotella increased in both PE groups, with additional increases in 43–108 and Paraprevotella in the 367 mg, and Bacteroides_H in the 700 mg groups (unadjusted post hoc P values). In addition, significant decreases in CAG-177, and unidentified Oscillospiraceae members and CAG-83 were observed in the PE 700 mg group (unadjusted post hoc P values). The placebo group showed no major changes at the phylum level, but significant slight increases in Tannerellaceae at the family level (unadjusted post hoc P values). At the genus level, Alistipes and Parabacteroides significantly increased, while Blautia significantly declined (unadjusted post hoc P values) (Fig. 4B).
Between-group comparisons showed significant (unadjusted post hoc P < 0.05) changes of CAG-313 for both PE groups vs. placebo at family level, as well as Pasteurellaceae and Brevibacteriaceae for PE 367 mg and Acidaminococcaceae for PE 700 mg. At the genus level, PE 367 mg of extract vs. placebo showed differences in Bacteroidaceae, Faecousia, Limivicinus, CAG-353, UBA1394, and Pasteurellaceae, whereas differences for the 700 mg dose included Methanobrevibacter_A, Actinomyces, and Pauljensenia (unadjusted post hoc P values). Detailed results are presented in Supplementary Table S5.
No significant differences in α or β diversity in either skin or fecal samples were detected. Also, Bray-Curtis and Weighted UniFrac analyses showed that study groups formed overlapping clusters, suggesting no differences in overall microbiota composition.
The overall mean compliance with the assigned product was 95.6 ± 6.6% without differences across the study groups. Adverse events (AEs) occurred in 9 participants (PE 367 mg in 3, PE 700 mg in 4, and placebo in 2) (Table 4). All cases were mild, except for two cases of itchy skin and one case of back pimples, which were of moderate severity. The association with the study product was assessed as “possible” in all cases, except for one case of increased serum potassium levels, which was assessed as “unlikely.”
The PE products were well tolerated.
Discussion
This study evaluated the effects of two doses of PE on reducing hyperpigmentation of a facial skin spot and improvement of other skin aging-related parameters. While the primary longitudinal analysis (LMM) did not demonstrate a significant treatment-by-visit interaction for MI of the facial spot, a baseline-adjusted analysis of the 12-week endpoint (ANCOVA) revealed that the lower dose PE 367 mg was associated with a more pronounced decrease in pigmentation after 12 weeks, with statistically significant differences compared to the placebo. Measurement of pigmentation of the facial spot using the DermoPrime system confirmed these findings. These results are consistent with the suggested effects of different pomegranate food products to decrease skin pigmentation reported in clinical studies. In a randomized controlled study, daily consumption of 240 mL of pomegranate juice (100 mg of punicalagin A/B and 23 mg of ellagic acid) and 1000 mg of a pomegranate extract (100 mg of punicalagin A/B and 44 mg of ellagic acid) for 12 weeks in healthy women that were irradiated with a defined dose of UV light, decreased the MI, although changes did not reach statistical significance2. In another clinical study, consumption of 480 mg/day of a combination of Polypodium leucotomos and pomegranate for 12 weeks reduced the MI of the right cheek with no extra UV irradiation as compared with baseline24. Also, oral consumption of two doses of pomegranate extract corresponding to 200 mg/day and 100 mg/day of ellagic acid for 4 weeks was associated with a protective effect on mild sunburn caused by irradiation with a defined dose of UV light, resulting in a decrease in pigmentation compared to the placebo-treated group25. Similarly, a clinical study of the effects of fermented pomegranate extract as functional drink and a cosmetic ingredient, suggested that both products had whitening properties due to their antimelanogenic activity compared to placebo31.
Interestingly, in a secondary exploratory analysis, the lower dose of PE also reduced the pigmentation of facial spotless skin, which is in accordance with results reported for pomegranate products24 and other dietary products such as polyphenols32 and β-carotene33 on skin pigmentation, suggesting a possible systemic photoprotection of PE consumption and its potential use as systemic skin lightening agent. It should be noted that the area of the skin evaluated was the face, a cutaneous region with some hyperpigmentation due to solar UV rays even if photoprotected. Results in placebo-treated participants showed a significant decrease of MI at 12 weeks probably because in the last months of the study the sun exposure by study participants was lower due to the time of year (late autumn-winter), and support exposure to UV radiation and hyperpigmentation of the facial skin.
The effects of PE on skin pigmentation might be due to the inhibition of melanin synthesis by tyrosinase in melanocytes. Melanin is the main determinant of skin color and contributes to protection against UV irradiation. Melanocytes synthetize melanin through melanogenesis34, a process regulated mainly by melanogenic enzymes, such as tyrosinase. However, hyperpigmentation caused by exposure to UV radiation and increased melanogenesis in sun-exposed areas produces premature photoaging of the skin and senescence in melanocytes7. Tyrosinase produces melanin through the oxidation of tyrosine substrates. Therefore, compounds with tyrosinase inhibitory activity have been proposed as agents for skin lightening15,21,22. In this regard, several in vitro studies have demonstrated the tyrosinase inhibitory effects of pomegranate extracts21,22 and a previous study of our group confirmed the inhibitory capacity of PE on tyrosinase activity in fibroblast cell models15.
The PE 367 mg dose provided the most remarkable effects on skin pigmentation, without a dose-effect relationship, which is similar to findings of pomegranate, punicalagin, and ellagic acid on different health targets shown in other studies25,35,36. A non-linear dose dependence has been reported for polyphenol compounds37, which suggests a biphasic dose-response with health benefits associated to the low dose stimulatory range38.
Regarding skin hydration and elasticity as secondary exploratory findings, a more favorable percentage change in hydration compared with placebo at 12 weeks was found for the 367 mg group, largely in the context of a decline in the placebo group. Elasticity findings were suggestive, particularly for the 700 mg group, but should be interpreted as secondary. However, in line with our findings, treatment with a pomegranate concentrate increased skin moisture of UV-induced skin photoaging in a hairless mice model23. In addition, daily consumption of Polypodium leucotomos/promegranate combination for 12 weeks improved transepithelial water loss in healthy volunteers24. Clinical studies performed with dietary extracts rich in polyphenol compounds also shown beneficial effects on skin hydration and elasticity14,39. The mechanisms reported by which polyphenolic extracts, including pomegranate extracts, may improve skin hydration and elasticity involve hyaluronic acid synthesis stimulating effects and improvement of the extracellular matrix status by modulation of collagen metabolism14,23. Interestingly, the results obtained in our previous study with PE extract using in vitro models showed positive effects on collagen and hyaluronic acid metabolism15, supporting the mechanisms by which PE exerts its beneficial effects on skin hydration and elasticity.
Pomegranate ellagitannins are not absorbed in the small intestine and undergo partial hydrolysis to form ellagic acid (EA)40. EA also presents poor absorption, and unabsorbed EA is further metabolized to urolithins by the microbiota in the large intestine, with urolithin A, urolithin B, and isourolithin A as end-products. Given that UAG has been linked to the biological activities of ellagitannin-containing foods41, we analyzed skin outcomes after excluding non-UAG producers showing that the effects of PE 700 mg on elasticity were greater considering the population capable of metabolizing pomegranate ellagitannins to form UAG.
Changes of oxidative stress biomarkers associated with PE consumption were not observed. However, a positive correlation between TBARS and DMEAG levels may indirectly suggest reduced lipid peroxidation, as higher absorption of the extract, reflected by increased DMEAG excretion, may be consistent with a greater reduction of TBARS. Although studies in healthy volunteers have demonstrated the antioxidant capacity of pomegranate extract consumption17,42, a meta-analysis of randomized controlled trials found that malondialdehyde (MDA), total antioxidant capacity, and glutathione peroxidase (GSH-Px) levels were significantly reduced after pomegranate consumption in subjects with any disease, whereas changes in healthy subjects were not significant43. It is possible that in healthy populations, a stress-induced challenge such as physical exercise, would be a more adequate approach to assess the effects of nutraceuticals on oxidative stress biomarkers44.
Exploratory microbiota analysis showed nominal changes. Treatment with PE influenced the composition of skin microbiota especially by increasing the abundance of Bifidobacterium, Lactobacillus, and Enterococcaceae family. Bifidobacterium and Lactobacillus contribute to maintaining a balanced and protective microbial environment for the skin45. Protective effects of genera of the Lactobacillaceae family include direct competition with skin pathogens by inhibiting their adhesion, producing antimicrobial metabolites, and influencing pathogen metabolism. Exogenously applied lactobacilli, such as L. rhamnosus GG and Limosilactibacillus reuteri DSM have been shown to exert both direct and indirect anti-pathogenic actions. Through direct binding interactions, lactobacilli or their lysates can prevent pathogen adhesion to keratinocytes or actively displace adhered pathogens46. On the other hand, nominal changes in fecal microbiota elicited by PE were characterized by an increase in Prevotella genera, a finding that has been also reported in a previous study of the health benefits of pomegranate consumption47. The increase in fermentative genera, particularly Prevotella, is typically associated with a fiber-rich diet, which is beneficial for gut health48. The observed modulation of skin and gut microbiota, including higher levels of beneficial genera such as Lacticaseibacillus and Bifidobacterium on the skin and increased fermentative taxa in the gut, is consistent with improved barrier function and reduced local inflammation. Notably, Akkermansia increased significantly in the 367 mg group compared to placebo, potentially reflecting improved mucosal and epithelial barrier regulation.
Notably, Akkermansia increased in the 367 mg group compared to placebo and this genus has been related with mucosal and epithelial barrier regulation. These microbiota findings are consistent with possible biological effects of PE, but they should not be interpreted as evidence of causal mechanism. Overall, although nominal, unadjusted microbiota differences were observed in selected taxa, these results should be interpreted cautiously because they were not robust to correction for multiple comparisons and no significant changes in overall alpha or beta diversity were detected.
The present results should be interpreted considering the limitations of the study. These include the single-center design; modest sample size; limited power for serum, urine, and microbiota outcomes; multiple secondary and exploratory endpoints; unadjusted microbiota comparisons; seasonal reduction in UV exposure and substantial placebo improvement in melanin index; possible influence of dietary, cosmetic, and sun-exposure adherence despite monitoring; and limited generalizability beyond healthy women with Fitzpatrick II–IV skin types and facial hyperpigmentation. Also, since the primary endpoint was not met, results of subsequent prespecified analyses should be considered exploratory and further powered studies are needed to confirm the present findings. Despite these limitations, analyses of a large number of skin aging-related features, serum and urine biomarkers, and skin and gut microbiota are strengths of the study. To our knowledge, a complete set of all these variables associated with pomegranate consumption in healthy women has not been previously evaluated.
Conclusions
Overall, in this small single-center trial, the primary mixed-model analysis did not demonstrate a significant longitudinal treatment effect of PE for MI of a facial spot. However, a secondary analysis of percentage change suggested a greater reduction in MI of a facial spot with the 367 mg dose compared with placebo at 12 weeks. Findings for improved skin hydration and elasticity, as well as observed shifts in beneficial bacterial genera (Lacticaseibacillus, Bifidobacterium, Akkermansia) should be interpreted as exploratory. These nominal changes in selected skin and gut taxa after supplementation require confirmation in larger studies powered for microbiota endpoints to further elucidate their potential role in skin health.
Data availability
The study protocol, de-identified participant-level data supporting the findings of this study, data dictionary, and statistical code are available from the corresponding author upon reasonable request, subject to approval by the study investigators and compliance with applicable ethical and data protection requirements. Requests should include a scientifically valid proposal and will be considered for verification and replication of the reported findings. The 16 S rRNA sequencing data are not publicly deposited because participant consent and ethics approval did not include unrestricted public deposition of sequencing data. Access to this data may be considered upon reasonable request under the same conditions.
References
Cevenini, E. et al. Human models of aging and longevity. Expert Opin. Biol. Ther. 8, 1393–1405. https://doi.org/10.1517/14712598.8.9.1393 (2008).
Henning, S. M. et al. Pomegranate juice and extract consumption increases the resistance to UVB-induced erythema and changes the skin microbiome in healthy women: a randomized controlled trial. Sci. Rep. 10, 14528. https://doi.org/10.1038/s41598-019-50926-2 (2019).
de Jager, T. L., Cockrell, A. E. & Du Plessis, S. S. Ultraviolet light induced generation of reactive oxygen species. Adv. Exp. Med. Biol. 996, 17–23. https://doi.org/10.1007/978-3-319-56017-5_2 (2017).
Quan, T. et al. Matrix-degrading metalloproteinases in photoaging. J. Investig Dermatol. Symp. Proc. 14, 20–24. https://doi.org/10.1038/jidsymp.2009.8 (2009).
Pérez-Sánchez, A., Barrajón-Catalán, E., Herranz-López, M. & Micol, V. Nutraceuticals for skin care: a comprehensive review of human clinical studies. Nutrients 10, 403. https://doi.org/10.3390/nu10040403 (2018).
Denat, L., Kadekaro, A. L., Marrot, L., Leachman, S. A. & Abdel-Malek, Z. A. Melanocytes as instigators and victims of oxidative stress. J. Invest. Dermatol. 134, 1512–1518. https://doi.org/10.1038/jid.2014.65 (2014).
Hughes, B. K. & Bishop, C. L. current understanding of the role of senescent melanocytes in skin ageing. Biomedicines 10, 3111. https://doi.org/10.3390/biomedicines10123111 (2022).
Matsuo, N. et al. Evaluation of the effects of mixed herb extract on skin based on anti-glycation effect: a randomized, double-blind, placebo-controlled, parallel-group study. Glycative Stress Res. 8, 98–109. https://doi.org/10.24659/gsr.8.2_98 (2021).
Souak, D. et al. challenging cosmetic innovation: the skin microbiota and probiotics protect the skin from UV-induced damage. Microorganisms 27, 936. https://doi.org/10.3390/microorganisms9050936 (2021).
Patra, V., Gallais Sérézal, I. & Wolf, P. Potential of skin microbiome, pro- and/or pre-biotics to affect local cutaneous responses to UV exposure. Nutrients 12, 1795. https://doi.org/10.3390/nu12061795 (2020).
Seth, D., Cheldize, K., Brown, D. & Freeman, E. F. Global burden of skin disease: inequities and innovations. Curr. Dermatol. Rep. 6, 204–210. https://doi.org/10.1007/s13671-017-0192-7 (2017).
Fitzgerald, R. et al. Update on facial aging. Aesthet. Surg. J. https://doi.org/10.1177/1090820X10378696 (2010).
Saliou, C. et al. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radic Biol. Med. 39, 154–160. https://doi.org/10.1016/s0891-5849(00)00445-7 (2001).
Segger, D. & Schönlau, F. Supplementation with Evelle improves skin smoothness and elasticity in a double-blind, placebo-controlled study with 62 women. J. Dermatolog Treat. 15, 222–226. https://doi.org/10.1080/09546630410033772 (2004).
Mariné-Casadó, R. et al. Pomegranate natural extract Pomanox® positively modulates skin health-related parameters in normal and UV-induced photoaging conditions in Hs68 human fibroblast cells. Int. J. Food Sci. Nutr. 74, 51–63. https://doi.org/10.1080/09637486.2022.2152189 (2022).
Farhat, G., Malla, J., Vadher, J. & Al-Dujaili, E. A. S. Effects of pomegranate extract on inflammatory markers and cardiometabolic risk factors in adults aged 55–70 years: a randomised controlled parallel trial. Nutrients 17, 1235. https://doi.org/10.3390/nu17071235 (2025).
Al-Dujaili, E. A. S., Casey, C. & Stockton, A. Antioxidant properties and beneficial cardiovascular effects of a natural extract of pomegranate in healthy volunteers: a randomized preliminary single-blind controlled study. Antioxid. (Basel). 11, 2124. https://doi.org/10.3390/antiox11112124 (2022).
Stockton, A. & Al-Dujaili, E. A. S. Effect of pomegranate extract consumption on satiety parameters in healthy volunteers: a preliminary randomized study. Foods 11, 2639. https://doi.org/10.3390/foods11172639 (2022).
Torregrosa-García, A. et al. pomegranate extract improves maximal performance of trained cyclists after an exhausting endurance trial: a randomised controlled trial. Nutrients 11, 721. https://doi.org/10.3390/nu11040721 (2019).
Farhat, G., Malla, J., Hanson, L., Vadher, J. & Al-Dujaili, E. A. S. Effects of pomegranate extract on IGF-1 levels and telomere length in older adults (55–70 years): findings from a randomised double-blinded controlled trial. Nutrients 17, 2974. https://doi.org/10.3390/nu17182974 (2025).
Verdú, D. et al. Pomegranate extract modulates oxidative stress by reducing basal ROS levels and protecting white blood cells from induced oxidative damage in aging mice. Int. J. Mol. Sci. 26, 5957. https://doi.org/10.3390/ijms26135957 (2025).
Stockton, A. V. E., Zangara, A. & Al-Dujaili, E. A. S. Chapter 10 - Investigating the acute effect of pomegranate extract on indicators of cognitive function in human volunteers: a double-blind placebo-controlled crossover trial. In Nutraceuticals in Brain Health and Beyond (ed. Ghosh, D.) 141–154 (Academic Press, 2021). https://doi.org/10.1016/B978-0-12-820593-8.00010-0.
Farhat, G. et al. Impact of pomegranate extract supplementation on physical and cognitive function in community-dwelling older adults aged 55–70 years: a randomised double-blind clinical trial. Geriatr. (Basel). 17, 29. https://doi.org/10.3390/geriatrics10010029 (2025).
Emanuele, E., Bertona, M. & Biagi, M. Comparative effects of a fixed Polypodium leucotomos/Pomegranate combination versus Polypodium leucotomos alone on skin biophysical parameters. Neuro Endocrinol. Lett. 38, 38–41 (2017).
Kasai, K., Yoshimura, M., Koga, T., Arii, M. & Kawasaki, S. Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin. J. Nutr. Sci. Vitaminol (Tokyo). 52, 383388. https://doi.org/10.3177/jnsv.52.383 (2006).
Chakkalakal, M. et al. Prospective randomized double-blind placebo-controlled study of oral pomegranate extract on skin wrinkles, biophysical features, and the gut-skin axis. J. Clin. Med. 11, 6724. https://doi.org/10.3390/jcm11226724 (2022).
Trinidad Rodríguez, I., Fernández Ballart, J., Cucó Pastor, G. & Biarnés Jordà, E. Arija Val, V. Validation of a short questionnaire on frequency of dietary intake: reproducibility and validity. Nutr. Hosp. 23, 242–252 (2008).
Baswan, S. M., Leverett, J. & Pawelek, J. Clinical evaluation of the lightening effect of cytidine on hyperpigmented skin. J. Cosmet. Dermatol. 18, 278–285. https://doi.org/10.1111/jocd.12784 (2019).
Tsuchiya, T., Fukui, Y., Izumi, R., Numano, K. & Zeida, M. Effects of oligomeric proanthocyanidins (OPCs) of red wine to improve skin whitening and moisturizing in healthy women - a placebo-controlled randomized double-blind parallel group comparative study. Eur. Rev. Med. Pharmacol. Sci. 24, 1571–1584. https://doi.org/10.26355/eurrev_202002_20215 (2020).
Suh, M. G., Hong, Y. H., Jung, E. Y. & Suh, H. J. Inhibitory effect of galactooligosaccharide on skin pigmentation. Prev. Nutr. Food Sci. 24, 321–326. https://doi.org/10.3746/pnf.2019.24.3.321 (2019).
Chan, L. P., Tseng, Y. P., Liu, C. & Liang, C. H. Fermented pomegranate extracts protect against oxidative stress and aging of skin. J. Cosmet. Dermatol. 21, 2236–2245. https://doi.org/10.1111/jocd.14379 (2022).
Gillbro, J. M. & Olsson, M. J. The melanogenesis and mechanisms of skin-lightening agents–existing and new approaches. Int. J. Cosmet. Sci. 33, 210–221. https://doi.org/10.1111/j.1468-2494.2010.00616.x (2011).
Boelsma, E., Hendriks, H. F. & Roza, L. Nutritional skin care: health effects of micronutrients and fatty acids. Am. J. Clin. Nutr. 73, 853–864. https://doi.org/10.1093/ajcn/73.5.853 (2001).
Bonaventure, J., Domingues, M. J. & Larue, L. Cellular and molecular mechanisms controlling the migration of melanocytes and melanoma cells. Pigment Cell. Melanoma Res. 26, 316–325. https://doi.org/10.1111/pcmr.12080 (2013).
Cervantes-Anaya, N. et al. Pomegranate and Its components, punicalagin and ellagic acid, promote antidepressant, antioxidant, and free radical-scavenging activity in ovariectomized rats. Front. Behav. Neurosci. 16, 836681. https://doi.org/10.3389/fnbeh.2022.836681 (2022).
El-Beih, N. M., Ramadan, G., El-Husseiny, E. A. & Hussein, A. M. Effects of pomegranate aril juice and its punicalagin on some key regulators of insulin resistance and oxidative liver injury in streptozotocin-nicotinamide type 2 diabetic rats. Mol. Biol. Rep. 46, 3701–3711. https://doi.org/10.1007/s11033-019-04813-8 (2019).
Kay, C. D., Hooper, L., Kroon, P. A., Rimm, E. B. & Cassidy, A. Relative impact of flavonoid composition, dose and structure on vascular function: a systematic review of randomised controlled trials of flavonoid-rich food products. Mol. Nutr. Food Res. 56, 1605–1616. https://doi.org/10.1002/mnfr.201200363 (2012).
Leri, M. et al. Healthy effects of plant polyphenols: molecular mechanisms. Int. J. Mol. Sci. 21, 1250. https://doi.org/10.3390/ijms21041250 (2020).
Marini, A. et al. Pycnogenol® effects on skin elasticity and hydration coincide with increased gene expressions of collagen type I and hyaluronic acid synthase in women. Skin. Pharmacol. Physiol. 25, 86–92. https://doi.org/10.1159/000335261 (2012).
Long, J. et al. Bioavailability and bioactivity of free ellagic acid compared to pomegranate juice. Food Funct. 10, 6582–6588. https://doi.org/10.1039/c9fo01683j (2019).
Venusova, E., Kolesarova, A., Horky, P. & Slama, P. Physiological and immune functions of punicalagin. Nutrients 13, 2150. https://doi.org/10.3390/nu13072150 (2021).
Gouda, M., Moustafa, A., Hussein, L. & Hamza, M. Three week dietary intervention using apricots, pomegranate juice or/and fermented sour sobya and impact on biomarkers of antioxidative activity, oxidative stress and erythrocytic glutathione transferase activity among adults. Nutr. J. 15, 52. https://doi.org/10.1186/s12937-016-0173-x (2016).
Lorzadeh, E. et al. Does pomegranate consumption improve oxidative stress? A systematic review and meta-analysis of randomized controlled clinical trials. Clin. Nutr. ESPEN. 47, 117–127. https://doi.org/10.1016/j.clnesp.2021.11.017 (2022).
Ammar, A. et al. Effects of pomegranate juice supplementation on oxidative stress biomarkers following weightlifting exercise. Nutrients 9, 819. https://doi.org/10.3390/nu9080819 (2017).
Lew, L. C., Gan, C. Y. & Liong, M. T. Dermal bioactives from lactobacilli and bifidobacteria. Ann. Microbiol. 63, 1047–1055. https://doi.org/10.1007/s13213-012-0561-1 (2013).
Delanghe, L. et al. The role of lactobacilli in inhibiting skin pathogens. Biochem. Soc. Trans. 49, 617–627. https://doi.org/10.1042/BST20200329 (2021).
Li, Z. et al. Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. Food Funct. 6, 2487–2495. https://doi.org/10.1039/c5fo00669d (2015).
Cronin, P., Joyce, S. A., O’Toole, P. W. & O’Connor, E. M. Dietary fibre modulates the gut microbiota. Nutrients 13, 1655. https://doi.org/10.3390/nu13051655 (2021).
Acknowledgements
The authors thank Farmacia Artur Pujol Perpiña and Mariluz Lorenzo for their support in measurement of participants’ skin parameters; Anna Antolín, laboratory technician at Eurecat for assistance in laboratory analyses; Lucía Tadeo Orellana from the Genomics facility for genomic analysis; José Manuel Barrera Gaviria from the Metabolomics facility for sequencing and mass spectrometry techniques; Adrià Cereto Massagué from the Bioinformatics facility for bioinformatic analysis; and Marta Pulido, MD, PhD, for editing the manuscript and editorial assistance.
Author information
Author notes
Josep M. del Bas
Present address: Departament de Bioquímica i Biotecnologia, Nutrigenomics Research Group, Universitat Rovira i Virgili, Reus, Tarragona, Spain
Nàdia Ortega-Olivé
Present address: Department of Food Technology, Engineering and Science, University of Lleida-Agrotecnio CERCA Centre, Lleida, Spain
Authors and Affiliations
Nutrition and Health Unit, Eurecat, Centre Tecnologic de Catalunya, Reus, Tarragona, Spain
Andrea Costa, Lorena Calderón-Pérez, Alicia Domingo-Tàrrech, Mª Josefina Ruiz de Azua, Bárbara Tello-Durán, Juan María Alcaide-Hidalgo, Natalia Calderón-Pérez, Marc Martí-Peiró, Nàdia Ortega-Olivé & Anna Crescenti
Biotechnology Area, Eurecat, Centre Tecnologic de Catalunya, Reus, Spain
Antoni Caimari & Josep M. del Bas
Nutrigenomics, Biomarkers and Risk Evaluation (NuBE) group, University of the Balearic Islands (UIB), Mallorca, Palma, Spain
Antoni Caimari
Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
Antoni Caimari
Euromed S.A, Mollet del Vallés, Barcelona, Spain
Andrea Zangara, Agustín Villar & Ester Risco
Centre for Omic Sciences (COS), Eurecat, Centre Tecnologic de Catalunya, Joint Unit Universitat Rovira i Virgili-EURECAT, Unique Scientific and Technical Infrastructures (ICTS), Reus, Tarragona, Spain
Antoni del Pino-Rius & Helena Torrell
Institute of Health Pere i Virgili (IISPV), Reus, Tarragona, Spain
Josep M. del Bas
Center of Environmental, Food and Toxicological Technology (TecnATox), Universitat Rovira I Virgili, Reus, Spain
Josep M. del Bas
Hospital Lleuger Antoni Gimbernat, Cambrils, Tarragona, Spain
Chantal Carpintero-Costa
Authors
- Andrea Costa
- Lorena Calderón-Pérez
- Alicia Domingo-Tàrrech
- Antoni Caimari
- Mª Josefina Ruiz de Azua
- Bárbara Tello-Durán
- Juan María Alcaide-Hidalgo
- Andrea Zangara
- Agustín Villar
- Ester Risco
- Natalia Calderón-Pérez
- Marc Martí-Peiró
- Antoni del Pino-Rius
- Helena Torrell
- Josep M. del Bas
- Nàdia Ortega-Olivé
- Chantal Carpintero-Costa
- Anna Crescenti
Contributions
Conceptualization, A.C. (Anna Crescenti), A.C. (Antoni Caimari), and J.M.D.B.; methodology, A.C. (Anna Crescenti), N.O.-O., A.C. (Andrea Costa), L.C.-P., A.D.-T., M.J.R.A., B.T.-D., M.M.-P., J.M.A.-H, A.P.-R., H.T.; data curation, A.C. (Anna Crescenti), A.C. (Andrea Costa), L.C.-P., A.D.-T., M.J.R.A., B.T.-D., M.M.-P., J.M.A.-H, A.P.-R., H.T.; project Administration, A.C. (Anna Crescenti); Supervision, A.C. (Antoni Caimari), N.O.-O., J.M.D.B.; investigation (products manufacturing), A.Z., A.V., E.R.; investigation (executed the study, obtained the samples, clinical details), A.C. (Anna Crescenti), A.C. (Andrea Costa), L.C.-P., A.D.-T., M.J.R.A., B.T.-D., M.M.-P., C.C.C.; investigation (performed laboratory analyses), J.M.A.‐H., N.C.-P., A.P.-R., H.T.; investigation (formal analysis), A.C. (Anna Crescenti), A.C. (Andrea Costa); funding acquisition, A.C. (Anna Crescenti), A.C. (Antoni Caimari), J.M.D.B.; writing-original draft preparation, A.C. (Anna Crescenti) and A.C. (Andrea Costa); review of the final draft, L.C.-P., A.D.-T., A.C. (Antoni Caimari), A.Z., A.V., E.R., M.J.R.A., B.T.-D., J.M.A-H., N.C.-P., M.M.-P., A.P.-R., H.T., J.M.D.B., N.O.-O., and C.C.C. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Correspondence to Anna Crescenti.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Costa, A., Calderón-Pérez, L., Domingo-Tàrrech, A. et al. Effects of pomegranate extract Pomanox on facial skin aging parameters: a randomized triple-blind placebo-controlled trial. Sci Rep 16, 30192 (2026). https://doi.org/10.1038/s41598-026-72115-8
Received: 03 December 2025
Accepted: 15 September 2026
Published: 13 October 2026
Version of record: 13 October 2026
DOI: https://doi.org/10.1038/s41598-026-72115-8
Keywords
来源:Nature 健康护理主题 · nature.com